Development of Etf-3-specific nanobodies to prevent Ehrlichia infection and LNP-mRNA delivery in cellular and murine models
Authors:
- 16 December 2024
- journal article
- research article
- Published by Elsevier in Microbiological Research
- Vol. 292, 128027
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 39 references indexed in Scilit:
- mRNA-based therapeutics: looking beyond COVID-19 vaccinesThe Lancet, 2024
- Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinicsAdvanced Drug Delivery Reviews, 2023
- STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2Nano Letters, 2023
- mRNA delivery in cancer immunotherapyActa Pharmaceutica Sinica B, 2023
- mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stabilityInternational Journal of Pharmaceutics, 2021
- Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 VaccinesACS Central Science, 2021
- Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis InfectionJAMA Network Open, 2020
- Leveraging mRNA Sequences and Nanoparticles to Deliver SARS‐CoV‐2 Antigens In VivoAdvanced Materials, 2020
- 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family membersNature, 2010
- Naturally occurring antibodies devoid of light chainsNature, 1993